Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article
Advertisement

Corrigendum Open Access | 10.1172/jci.insight.144624

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

Michael P. Pender, Peter A. Csurhes, Corey Smith, Nanette L. Douglas, Michelle A. Neller, Katherine K. Matthews, Leone Beagley, Sweera Rehan, Pauline Crooks, Tracey J. Hopkins, Stefan Blum, Kerryn A. Green, Zara A. Ioannides, Andrew Swayne, Blake T. Aftab, Kaye D. Hooper, Scott R. Burrows, Kate M. Thompson, Alan Coulthard, and Rajiv Khanna

Find articles by Pender, M. in: JCI | PubMed | Google Scholar

Find articles by Csurhes, P. in: JCI | PubMed | Google Scholar

Find articles by Smith, C. in: JCI | PubMed | Google Scholar

Find articles by Douglas, N. in: JCI | PubMed | Google Scholar

Find articles by Neller, M. in: JCI | PubMed | Google Scholar

Find articles by Matthews, K. in: JCI | PubMed | Google Scholar

Find articles by Beagley, L. in: JCI | PubMed | Google Scholar

Find articles by Rehan, S. in: JCI | PubMed | Google Scholar

Find articles by Crooks, P. in: JCI | PubMed | Google Scholar

Find articles by Hopkins, T. in: JCI | PubMed | Google Scholar

Find articles by Blum, S. in: JCI | PubMed | Google Scholar

Find articles by Green, K. in: JCI | PubMed | Google Scholar

Find articles by Ioannides, Z. in: JCI | PubMed | Google Scholar

Find articles by Swayne, A. in: JCI | PubMed | Google Scholar

Find articles by Aftab, B. in: JCI | PubMed | Google Scholar

Find articles by Hooper, K. in: JCI | PubMed | Google Scholar

Find articles by Burrows, S. in: JCI | PubMed | Google Scholar

Find articles by Thompson, K. in: JCI | PubMed | Google Scholar

Find articles by Coulthard, A. in: JCI | PubMed | Google Scholar

Find articles by Khanna, R. in: JCI | PubMed | Google Scholar

Published October 15, 2020 - More info

Published in Volume 5, Issue 20 on October 15, 2020
JCI Insight. 2020;5(20):e144624. https://doi.org/10.1172/jci.insight.144624.
© 2020 sclerosis et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published October 15, 2020 - Version history
View PDF

Related article:

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis
Michael P. Pender, … , Alan Coulthard, Rajiv Khanna
Michael P. Pender, … , Alan Coulthard, Rajiv Khanna
A phase I clinical trial of EBV-specific T cell therapy in multiple sclerosis demonstrated safety, and 7 patients with progressive multiple sclerosis showed clinical improvement.
Clinical Medicine Clinical trials Neuroscience

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

  • Text
  • PDF
Abstract

BACKGROUND. Increasing evidence indicates a role for EBV in the pathogenesis of multiple sclerosis (MS). EBV-infected autoreactive B cells might accumulate in the CNS because of defective cytotoxic CD8+ T cell immunity. We sought to determine the feasibility and safety of treating progressive MS patients with autologous EBV-specific T cell therapy. METHODS. An open-label phase I trial was designed to treat 5 patients with secondary progressive MS and 5 patients with primary progressive MS with 4 escalating doses of in vitro–expanded autologous EBV-specific T cells targeting EBV nuclear antigen 1, latent membrane protein 1 (LMP1), and LMP2A. Following adoptive immunotherapy, we monitored the patients for safety and clinical responses. RESULTS. Of the 13 recruited participants, 10 received the full course of T cell therapy. There were no serious adverse events. Seven patients showed improvement, with 6 experiencing both symptomatic and objective neurological improvement, together with a reduction in fatigue, improved quality of life, and, in 3 patients, reduced intrathecal IgG production. All 6 patients receiving T cells with strong EBV reactivity showed clinical improvement, whereas only 1 of the 4 patients receiving T cells with weak EBV reactivity showed improvement (P = 0.033, Fisher’s exact test). CONCLUSION. EBV-specific adoptive T cell therapy was well tolerated. Clinical improvement following treatment was associated with the potency of EBV-specific reactivity of the administered T cells. Further clinical trials are warranted to determine the efficacy of EBV-specific T cell therapy in MS. TRIAL REGISTRATION. Australian New Zealand Clinical Trials Registry, ACTRN12615000422527. FUNDING. MS Queensland, MS Research Australia, Perpetual Trustee Company Ltd., and donations from private individuals who wish to remain anonymous.

Authors

Michael P. Pender, Peter A. Csurhes, Corey Smith, Nanette L. Douglas, Michelle A. Neller, Katherine K. Matthews, Leone Beagley, Sweera Rehan, Pauline Crooks, Tracey J. Hopkins, Stefan Blum, Kerryn A. Green, Zara A. Ioannides, Andrew Swayne, Blake T. Aftab, Kaye D. Hooper, Scott R. Burrows, Kate M. Thompson, Alan Coulthard, Rajiv Khanna

×

Original citation: JCI Insight. 2018;3(22):e124714. https://doi.org/10.1172/jci.insight.124714

Citation for this corrigendum: JCI Insight. 2020;5(20):e144624. https://doi.org/10.1172/jci.insight.144624

During the preparation of this manuscript, errors relating to data for BVMT-TL, BVMT-DR, PASAT3, and PASAT2 were inadvertently introduced into Figure 3C. Several of the data points have changed, but there are only minimal changes in the mean values and standard deviations. In addition, in Results, in the section Clinical outcomes following T cell therapy, the P value for PASAT3 is incorrect. However, after applying Bonferroni’s correction for multiple comparisons, the new P value still does not reach significance. The correct sentence and figure part are below. The online HTML and PDF versions of the manuscript have been updated to reflect these changes.

Figure 3

Statistically significant, or nearly significant, increases in attainment were observed at week 27 across two measures, the Controlled Oral Word Association Test (COWAT, a verbal fluency test) and the Paced Auditory Serial Addition Test (PASAT3, a working memory/processing speed task) (P = 0.074 and P = 0.0356 respectively, paired 2-tailed t test); however, after applying the Bonferroni correction for multiple comparisons, these P values no longer reached significance.

The authors regret the errors.

Footnotes

See the related article at Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis.

Version history
  • Version 1 (October 15, 2020): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts